These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 16102610

  • 1. Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
    Altundag O, Altundag K, Boruban C, Silay YS.
    Lung Cancer; 2005 Sep; 49(3):429. PubMed ID: 16102610
    [No Abstract] [Full Text] [Related]

  • 2. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
    Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH.
    Cancer; 2007 Dec 15; 110(12):2775-84. PubMed ID: 17948911
    [Abstract] [Full Text] [Related]

  • 3. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    Li N, Li H, Su F, Li J, Ma X, Gong P.
    Int J Clin Exp Pathol; 2015 Dec 15; 8(8):9010-20. PubMed ID: 26464643
    [Abstract] [Full Text] [Related]

  • 4. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
    Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM.
    J Thorac Oncol; 2008 Feb 15; 3(2):117-24. PubMed ID: 18303430
    [Abstract] [Full Text] [Related]

  • 5. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3381-8. PubMed ID: 16740761
    [Abstract] [Full Text] [Related]

  • 6. [The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell].
    Li SS, Zhang X, Xu J, Xie L, Qiu Y, Shu X, Tian Y.
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Sep 01; 23(18):817-20, 823. PubMed ID: 20120857
    [Abstract] [Full Text] [Related]

  • 7. New therapy targets resistant non-small-cell lung cancers.
    Jenks S.
    J Natl Cancer Inst; 2014 Nov 01; 106(11):. PubMed ID: 25421346
    [No Abstract] [Full Text] [Related]

  • 8. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
    Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ.
    Clin Cancer Res; 2005 Sep 01; 11(17):6097-9. PubMed ID: 16144906
    [No Abstract] [Full Text] [Related]

  • 9. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P.
    Clin Cancer Res; 2008 Apr 01; 14(7):2088-94. PubMed ID: 18381949
    [Abstract] [Full Text] [Related]

  • 10. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
    Ko JC, Wang LH, Jhan JY, Ciou SC, Hong JH, Lin ST, Lin YW.
    Lung Cancer; 2009 Sep 01; 65(3):290-8. PubMed ID: 19157634
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
    Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT, Duffield-Lillico AJ, Subbaramaiah K, Dannenberg AJ.
    Clin Cancer Res; 2005 Jun 01; 11(11):4191-7. PubMed ID: 15930356
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A.
    J Thorac Oncol; 2007 Apr 01; 2(4):299-305. PubMed ID: 17409801
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
    Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM.
    Cancer; 2015 Sep 15; 121(18):3298-306. PubMed ID: 26033830
    [Abstract] [Full Text] [Related]

  • 14. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.
    Cell Death Dis; 2015 Aug 06; 6(8):e1850. PubMed ID: 26247735
    [Abstract] [Full Text] [Related]

  • 15. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X, Yue P, Zhou Z, Khuri FR, Sun SY.
    J Natl Cancer Inst; 2004 Dec 01; 96(23):1769-80. PubMed ID: 15572759
    [Abstract] [Full Text] [Related]

  • 16. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H.
    Clin Cancer Res; 2006 Aug 15; 12(16):4989-99. PubMed ID: 16914589
    [Abstract] [Full Text] [Related]

  • 17. Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
    Backlund MG, Amann JM, Johnson DH.
    J Clin Oncol; 2008 Feb 20; 26(6):825-7. PubMed ID: 18281650
    [No Abstract] [Full Text] [Related]

  • 18. Years of research come to fruition with launch of oral cancer prevention trial.
    Nelson NJ.
    J Natl Cancer Inst; 2006 Jan 18; 98(2):88-9. PubMed ID: 16418508
    [No Abstract] [Full Text] [Related]

  • 19. Association between cyclooxygenase and epidermal growth factor receptor pathways in non-small cell lung cancer.
    Ates M, Altundag O, Aktolga S, Altundag K.
    J Thorac Cardiovasc Surg; 2005 Nov 18; 130(5):1484-5; author reply 1485. PubMed ID: 16256823
    [No Abstract] [Full Text] [Related]

  • 20. Erlotinib hydrochloride.
    Minna JD, Dowell J.
    Nat Rev Drug Discov; 2005 May 18; Suppl():S14-5. PubMed ID: 15962526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.